

# NMDP<sup>SM</sup> Amy Strelzer Manasevit Research Program

## Request for applications

NMDP is proud to announce our annual request for applications to the NMDP Amy Strelzer Manasevit Research Program for the study of post-transplant complications (Amy Research Program). The Amy Research Program is one of the largest and most coveted grants in the field of hematopoietic cell transplantation (HCT) and cell therapy (CT).

The Amy Research Program aims to help launch the careers of researchers seeking to discover solutions to potentially life-threatening post-transplant or post-cell therapy complications like infection, organ toxicity, relapse and graft-versus-host disease.

NMDP prioritizes studies evaluating strategies to improve outcomes following HLA-mismatched unrelated donor (MMUD) transplantation, cell therapies involving unrelated donors, survivorship or supportive care.

The Amy Research Program focuses on early career support in order to attract new talent to the field and to encourage researchers to study ways to alleviate therapy-associated complications. Amy Scholars receive a maximum support of \$400,000 over a five-year period.

Access the [Application for the 2026 Amy Research Program](#) and [Application Instructions](#).

## Proposal requirements

- Research proposals must address complications arising after allogeneic HCT or cell therapy directed at a disease traditionally treated by HCT.
- The cell therapy being studied does not have to be given in conjunction with HCT but should have the intent to bridge to HCT. Therefore, cell therapies with targets or indications outside hematologic malignancies are not eligible. Post-transplant or post-cell therapy complications are defined as acute and late complications, including disease relapse.
- Proposals involving mismatched unrelated donor (MMUD) HCT are preferred. Such proposals could include the use of data and/or samples from NMDP-sponsored, CIBMTR-led MMUD clinical trials as available. Inquiries should be made prior to application submission.
- Submissions can only include one principal investigator (i.e., the applicant) and no co-investigators.
  - Proposals may describe either clinical or pre-clinical investigations with necessary regulatory approval as necessary (e.g., IRB, IACUC, etc.).

### Examples of clinical investigation:

- Observational human research

- Prospective interventional clinical trials in humans
- Ancillary laboratory studies performed in conjunction with a human prospective clinical trial

#### Pre-clinical investigation description:

Laboratory-based human and/or animal studies designed to test the mechanisms, safety and efficacy of an intervention prior to or in conjunction with its application in humans.

### Applicant qualification criteria

- Applicants must hold a doctoral degree (MD, PhD, DO or equivalent) received within the past 10 years (Jan. 1, 2016, or later) in a field specific to the award criteria.
- If an applicant holds more than one relevant doctoral degree, eligibility will be based on the most recent degree attained.
- Applicants may not hold a NIH R01 or equivalent research grant at the time of the award.
- Applicants must be employed by a U.S. research, medical, or academic facility. Awardees may transfer the award to another facility during the award period if a written request with justification is submitted to NMDP for review and approval.
- Applicants must hold U.S. citizenship or have permanent residency. If a foreign citizen, applicants must carry a valid U.S. visa.
- Applicants whose careers have been interrupted may request an extension of the degree requirement by completing the [Extension Request Form](#) and emailing it to [asmgrant@nmdp.org](mailto:asmgrant@nmdp.org).
- If credentials for eligibility are uncertain, please email [asmgrant@nmdp.org](mailto:asmgrant@nmdp.org).
- **Proposals must be submitted by 2 p.m. Central Time on or before Thursday, August 7, 2025.**

### Program awards

- Up to two proposals will be funded by the Amy Research Program. Depending on the number of quality proposals received, at least one clinical proposal and one pre-clinical proposal will be awarded.
- A total of \$400,000 in support is paid over five years. Payments will be made as follows:
  - At grant receipt
  - At six-month reporting milestones
  - At final report
- Grant award recipients will use data, samples, physical collections and other supporting materials solely for performing the research activities as defined under their grant award. Any other proposed use by the grant recipient will require NMDP's prior written approval.

- A review panel will select up to two scholars for the funding period, July 1, 2026, through June 30, 2031. **Awardees will be announced at the 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held Feb. 4–8, 2026.**

## Grant history

The NMDP Amy Research Program was established in 1997 to honor the memory of Amy Strelzer Manasevit. A vibrant young mother of two children, Amy was diagnosed with multiple myeloma in 1993. After receiving a successful bone marrow transplant, she succumbed to pneumonia and passed away, just six weeks after returning home. The Manasevit family and their friends partnered with NMDP to establish the research program with the hope they could prevent other families from losing their loved ones to complications arising from HCT. To date, the Amy Research Program has supported 55 scholars and at least 12 post-doctoral fellows with financial investments of nearly \$12.5 million since 1998. Amy Scholars have gone on to win more than \$250 million in subsequent government grants following their Amy Research Program awards. NMDP appreciates the [financial contributions](#) that fund this critical research fellowship.

[Contact us](#) for more information about the NMDP Amy Strelzer Manasevit Research Program.